131 related articles for article (PubMed ID: 24296298)
1. DPP-IV inhibitors: Beyond glycaemic control?
Kwok AJ; Mashar M; Khavandi K; Sabir I
Trends Cardiovasc Med; 2014 May; 24(4):157-64. PubMed ID: 24296298
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular pleiotropic actions of DPP-4 inhibitors: a step at the cutting edge in understanding their additional therapeutic potentials.
Balakumar P; Dhanaraj SA
Cell Signal; 2013 Sep; 25(9):1799-803. PubMed ID: 23707531
[TBL] [Abstract][Full Text] [Related]
3. The dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus: cardiovascular safety.
Green JB
Postgrad Med; 2012 Jul; 124(4):54-61. PubMed ID: 22913894
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular effects of the DPP-4 inhibitors.
Jose T; Inzucchi SE
Diab Vasc Dis Res; 2012 Apr; 9(2):109-16. PubMed ID: 22337893
[TBL] [Abstract][Full Text] [Related]
5. Dipeptidyl peptidase-4 inhibitors: multitarget drugs, not only antidiabetes drugs.
Zhao Y; Yang L; Zhou Z
J Diabetes; 2014 Jan; 6(1):21-9. PubMed ID: 23683065
[TBL] [Abstract][Full Text] [Related]
6. Clinical implications of cardiovascular preventing pleiotropic effects of dipeptidyl peptidase-4 inhibitors.
Chrysant SG; Chrysant GS
Am J Cardiol; 2012 Jun; 109(11):1681-5. PubMed ID: 22425330
[TBL] [Abstract][Full Text] [Related]
7. Dipeptidyl peptidase IV and its inhibitors: therapeutics for type 2 diabetes and what else?
Juillerat-Jeanneret L
J Med Chem; 2014 Mar; 57(6):2197-212. PubMed ID: 24099035
[TBL] [Abstract][Full Text] [Related]
8. Impact of dipeptidyl-peptidase 4 inhibitors on cardiovascular diseases.
Xie W; Song X; Liu Z
Vascul Pharmacol; 2018 Oct; 109():17-26. PubMed ID: 29879463
[TBL] [Abstract][Full Text] [Related]
9. Potential impact of dipeptidyl peptidase-4 inhibitors on cardiovascular pathophysiology in type 2 diabetes mellitus.
Davidson MH
Postgrad Med; 2014 May; 126(3):56-65. PubMed ID: 24918792
[TBL] [Abstract][Full Text] [Related]
10. DPP-4 inhibitors in the treatment of type 2 diabetes.
Duez H; Cariou B; Staels B
Biochem Pharmacol; 2012 Apr; 83(7):823-32. PubMed ID: 22172989
[TBL] [Abstract][Full Text] [Related]
11. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety.
Deacon CF; Holst JJ
Expert Opin Pharmacother; 2013 Oct; 14(15):2047-58. PubMed ID: 23919507
[TBL] [Abstract][Full Text] [Related]
12. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
Deacon CF; Mannucci E; Ahrén B
Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular effects of DPP-4 inhibition: beyond GLP-1.
Fadini GP; Avogaro A
Vascul Pharmacol; 2011; 55(1-3):10-6. PubMed ID: 21664294
[TBL] [Abstract][Full Text] [Related]
14. [Towards evidence-based medicine: large-scale intervention trials with dipeptidyl peptidase-4 inhibitors].
Avogaro A
G Ital Cardiol (Rome); 2012 Dec; 13(12 Suppl 1):23S-31S. PubMed ID: 23258126
[TBL] [Abstract][Full Text] [Related]
15. DPP IV inhibitors: successes, failures and future prospects.
Kshirsagar AD; Aggarwal AS; Harle UN; Deshpande AD
Diabetes Metab Syndr; 2011; 5(2):105-12. PubMed ID: 22813415
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes.
Scheen AJ
Postgrad Med; 2013 May; 125(3):7-20. PubMed ID: 23748503
[TBL] [Abstract][Full Text] [Related]
17. Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4).
Thornberry NA; Gallwitz B
Best Pract Res Clin Endocrinol Metab; 2009 Aug; 23(4):479-86. PubMed ID: 19748065
[TBL] [Abstract][Full Text] [Related]
18. DPP4 in cardiometabolic disease: recent insights from the laboratory and clinical trials of DPP4 inhibition.
Zhong J; Maiseyeu A; Davis SN; Rajagopalan S
Circ Res; 2015 Apr; 116(8):1491-504. PubMed ID: 25858071
[TBL] [Abstract][Full Text] [Related]
19. Food protein hydrolysates as a source of dipeptidyl peptidase IV inhibitory peptides for the management of type 2 diabetes.
Power O; Nongonierma AB; Jakeman P; FitzGerald RJ
Proc Nutr Soc; 2014 Feb; 73(1):34-46. PubMed ID: 24131508
[TBL] [Abstract][Full Text] [Related]
20. Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.
Boland CL; Degeeter M; Nuzum DS; Tzefos M
Ann Pharmacother; 2013 Apr; 47(4):490-505. PubMed ID: 23548652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
